Table 2. Comorbidities of patients included in the study.

N/A: not applicable; No.: number of patients

Study	Hypertension No. (%)		Diabetic retinopathy No. (%)		Diabetic neuropathy No. (%)		History of cardiovascular diseases No. (%)		Heart failure No. (%)		Peripheral arterial occlusive disease No. (%)		Ischemic stroke No. (%)
	Finerenone	Placebo	Finerenone	Placebo	Finerenone	Placebo	Finerenone	Placebo	Finerenone	Placebo	Finerenone	Placebo	Finerenone	Placebo
Bakris (2015) [13]	685(94.2)	89 (94.7)	149(20.4)	19 (20.2)	139(19.1)	27(28.7)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Katayama (2017) [17]	84 (100)	12 (100)	40 (47.6)	5 (41.7)	30 (35.7)	6 (50)	15(17.8)	3(25)	N/A	N/A	N/A	N/A	N/A	N/A
Bakris (2020) [14]	2737 (96.6)	2768 (97.4)	1312 (46.3)	1351 (47.6)	738 (26.1)	716 (25.2)	1303 (46.0)	1302 (45.8)	195 (6.9)	241 (8.5)	470 (16.6)	453 (15.9)	329 (11.6)	360 (12.7)
Bertram (2021) [10]	3544 (96.1)	3517 (95.9)	1193 (32.4)	1098 (30.0)	1046 (28.4)	990 (27.0)	1676 (45.5)	1654 (45.1)	290 (7.9)	281 (7.7)	587 (15.9)	575 (15.7)	442 (12.0)	425 (11.6)
Gerasimos (2021) [15]	2737(96.6)	2768(97.3)	1312(46.3)	1351(47.5)	742(26.1)	722(25.4)	1303(45.9)	1302(45.8)	195 (6.8)	241(8.4)	N/A	N/A	N/A	N/A
Agarwal (2022) [5]	6281 (96.3)	6285 (96.6)	2505 (38.4)	2449 (37.6)	1788 (27.4)	1712(26.3)	2979 (45.7)	2956 (45.4)	485 (7.4)	522 (8.0)	1057 (16.2)	1028 (15.8)	771 (11.8)	785 (12.1)
Gerasimos (2022)[16]	3436(93.2)	3398(92.6)	N/A	N/A	N/A	N/A	1676(45.4)	1654(45.1)	290 (7.8)	281 (7.6)	N/A	N/A	N/A	N/A